Table 1. Patient characteristics.
| Characteristics | Value (N=15) |
|---|---|
| Age (years), median [range] | 70 [47–80] |
| Sex, n (%) | |
| Male | 13 (86.7) |
| Female | 2 (13.3) |
| Performance status, n (%) | |
| 0 | 3 (20.0) |
| 1 | 12 (80.0) |
| Number of prior treatment, n (%) | |
| 1 | 10 (66.7) |
| 2 | 5 (33.3) |
| Prior immune checkpoint inhibitors, n (%) | |
| No | 10 (66.7) |
| Yes | 5 (33.3) |
| Prior bevacizumab, n (%) | |
| No | 13 (86.7) |
| Yes | 2 (13.3) |
| Stage (at diagnosis), n (%) | |
| III | 4 (26.7) |
| IV | 7 (46.7) |
| Relapse, n (%) | 4 (26.7) |
| Smoking, n (%) | |
| Never | 4 (26.7) |
| Past/current | 11 (73.3) |
| Prior pleurodesis, n (%) | |
| No | 14 (93.3) |
| Yes | 1 (6.7) |
| Pathology, n (%) | |
| Adeno | 13 (86.7) |
| Squamous | 1 (6.7) |
| Pleomorphic | 1 (6.7) |
| EGFR mutation, n (%) | |
| No | 13 (86.7) |
| Yes | 2 (13.3) |
EGFR, epidermal growth factor receptor.